多发性骨髓瘤患者基质细胞衍生因子-1α、CD44v6撕表达的研究

Study on SDF-loL and CD44v6 expression in multiple myeloma patients

目的探讨基质细胞衍生因子-1α（SDF-1α）、CD44v6（一种变异的CD44受体）在多发性骨髓瘤（MM）中的表达水平及其与病情进展的关系。方法用酶联免疫吸附试验（ELISA）检测24例MM患者[14例初发和复发MM患者（初发和复发MM组），10例病情稳定MM患者（病情稳定MM组）1和15位健康骨髓移植供者或非肿瘤良性贫血患者（对照组）的骨髓单个核细胞（MNC）和骨髓基质细胞（BMSC）培养上清的SDF-1d、CD。水平。结果初发和复发MM组MNC培养上清的SDF-1α、CD44v6表达水平[（7232．41±2644．97）Pg／ml和（34．344±13．20）ng／m1]显著高于病情稳定MM组[（2315．49±748．29）Pg／ml和（15．694±5．28）ng／m1]（t=6．25、t=7．82；均P〈0．05）和对照组[（1149．524±636．06）Pg／ml和（4．854±3．62）ng／m1]（t=4．60、t=7．61；均P〈0．05）。病情稳定MM组SDF-1仪、CD‰水平显著高于对照组（t=2．99、t=4．87；均P〈0．05）。9例初发和复发MM组的BMSC与人类骨髓瘤细胞系细胞U266加入rhlL-6进行混合培养后，SDF-1α水平[（6180．254-5925．38）Pg／m1]显著高于5例对照组BMSC[（1021．13±358．65）Pg／m1]和9例初发和复发MM组[（1004．074±727．36）Pg／ml]（t=2．66、t=2．42；均P〈0．05）。而其他BMSC各组间的SDF-1α水平差异无统计学意义（P〉0．05）。SDF-1α与CD。两者表达水平呈正相关（r=0．51，P=0．03）。结论SDF-1α、CD。水平升高与MM的病情进展或发病有关，也可能与MM的肿瘤浸润过程有关；而这些体内过程可能需骨髓瘤细胞和BMSC与IL-6、SDF-1α和CD44v6等因素协同完成。

Objective To explore the relationship of stromal derived factor lα （SDF-lα） and CD44 variant isoforms （CD44v6） with progress of multiple myeloma （MM）. Methods Bone marrow mononuelear cells （MNCs） and bone marrow stromal cells （BMSCs） from 24 cases of MM patients （14 cases of untreated and relapsed and 10 cases of stable MM patients） and 15 cases of subjects were investigated as potential SDF-lot and CD44v6 product. The level of SDF-lα and CD44v6 of the conditioned media from MM patients and subjects were analyzed by ELISA. Results The level of SDF-lα and CD44v66 from MNCs in untreated and relapsed MM patients [（7232.41 ± 2644.97） pg/ml and （34.34 ± 13.20） ng/ml] were significantly higher than stable MM patients [（2315.49±748.29） pg/ml and （15.69 ± 5.28） ng/ml] （t = 6.25, t = 7.82, P 〈 0.05） and 15 subjects [ （1149.52 ± 636.06） pg/ml and （4.85 ±3.62） ng/ml] （t = 4.60, t = 7.61, P〈 0.05）. The level of SDF-lα in stable MM patients was different from healthy subjects （P 〈0.05）, but the level of CD44v6 in stable MM patients was not different from controls. The level of SDF-lα and CD44v6 in stable MM patients were significantly higher than health subjects （t = 2.99, t = 4.87, P 〈0.05）. The level of SDF-lα was also detected from BMSCs of MM patients. When human MM cell lines U266 were adhered to BMSCs of 9 untreated and relapsed MM patients, and added rhIL-6 to it, there was significant increase of SDF-1α, compared with BMSCs in subjects and MM patients. The expression level of SDF-lα was correlated with the level of CD44v6 （r =0.51, P =0.03）. Conclusion The increase of SDF-lα （may be produced by myeloma cells and BMSCs） and CD44v6 （may be produced by myeloma cells） activity is associated with the progress or pathogenesis of MM, and may be involved with tumor invasion. The completion of these processes in vivo may need participation of myeloma cells, BMSCs, IL-6, SDF-lct and CD44v6.